ReviR Therapeutics Doses First Patient in RTX-117 Phase 1 Trial Following Dual U.S. and China IND Clearances
AI-driven biotech advances clinical development of RNA-modulating therapy targeting rare neurological diseases Charcot-Marie-Tooth and Vanishing White Matter disease.